NCI Materials
Published Trial Results
Professional Education
NCI Materials
On January 5, 2006, the National Cancer Institute (NCI) released a clinical announcement concerning recommended treatment for advanced ovarian cancer.
Based on the results of eight phase III clinical trials, the NCI is encouraging doctors to follow surgery with a combination of two drug-delivery methods: intravenous (by vein) and intraperitoneal (directly into the abdomen). The combined approach, though more toxic, extends overall survival for women with advanced ovarian cancer by about a year compared to intravenous delivery alone.
Epithelial ovarian carcinoma is the leading cause of death from gynecologic malignancies in the developed world. To date, no effective screening regimen for ovarian cancer has been identified. More than half of women with ovarian cancer present with advanced-stage disease (stage III or IV) at the time of diagnosis.
For more information, please see the links in this and the following sections.
NCI Issues Clinical Announcement for Preferred Method of Treatment for Advanced Ovarian Cancer 3
(Posted: 01/04/2006) - NCI today issued an announcement encouraging treatment with anticancer drugs via two methods, after surgery, for women with advanced ovarian cancer. The combined methods, which deliver drugs into a vein and directly into the abdomen, extend overall survival for women with advanced ovarian cancer by about a year.
Questions and Answers 4
NCI Clinical Announcement: Intraperitoneal Chemotherapy for Ovarian Cancer 5
The Jan. 5, 2006, NCI clinical announcement concerning the preferred method of treatment for advanced ovarian cancer, based on the results of trials investigating the use of intraperitoneal administration of anticancer drugs after surgery.
Published Trial Results
Intraperitoneal Chemotherapy of Ovarian Cancer: A Review, With a Focus on Practical Aspects of Treatment 6
Abstract of article, from the Feb. 20, 2006, issue of the Journal of Clinical Oncology (J Clin Oncol. 2006 Feb 6; [Epub ahead of print]).
Intraperitoneal Cisplatin and Paclitaxel in Ovarian Cancer 7
Free access to the full article from the Jan. 5, 2006 issue of the New England Journal of Medicine. There is also an accompanying editorial 8.
Intraperitoneal catheter outcomes in a phase III trial of intravenous versus intraperitoneal chemotherapy in optimal stage III ovarian and primary peritoneal cancer: A Gynecologic Oncology Group study 9
PDF of the full article from the Jan. 2006 issue of Gynecologic Oncology. There is also an accompanying editorial 10.
Intraperitoneal Cisplatin Versus No Further Treatment: 8-year results of EORTC 55875 11
Abstract of article, from the Nov.-Dec. 2003 issue of the International Journal of Gynecological Cancer (Int J Gynecol Cancer. 2003 Nov-Dec;13 Suppl 2:196-203).
Phase III trial of standard-dose intravenous cisplatin plus paclitaxel versus moderately high-dose carboplatin followed by intravenous paclitaxel and intraperitoneal cisplatin in small-volume stage III ovarian carcinoma 12
Abstract of article, from the Feb. 15, 2001, issue of the Journal of Clinical Oncology (J Clin Oncol. 2001 Feb 15;19(4):1001-7).
Intraperitoneal cisplatin-based chemotherapy vs. intravenous cisplatin-based chemotherapy for stage III optimally cytoreduced epithelial ovarian cancer 13
Abstract of article, from the Jan. 2001 issue of the International Journal of Gynecology & Obstetrics (Int J Gynaecol Obstet. 2001 Jan;72(1):55-60).
Intraperitoneal versus intravenous cisplatin in combination with intravenous cyclophosphamide and epidoxorubicin in optimally cytoreduced advanced epithelial ovarian cancer 14
Abstract of article, from the Feb. 2000 issue of journal Gynecologic Oncology (Gynecol Oncol. 2000 Feb;76(2):157-62).
A comparative study of intraperitoneal carboplatin versus intravenous carboplatin with intravenous cyclophosphamide in both arms as initial chemotherapy for stage III ovarian cancer 15
Abstract of article, from the 1999 issue of the journal Oncology (Oncology. 1999;56(4):291-6).
Intraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclophosphamide for stage III ovarian cancer 16
Abstract of article, from the Dec. 26, 1996, issue of the New England Journal of Medicine (N Engl J Med. 1996 Dec 26;335(26):1950-5).
Professional Education
Gynecologic Oncology Group (GOG) 17
The GOG is one of the National Cancer Institute's funded cooperative cancer research groups. GOG is the only group which focuses its research on women with pelvic malignancies, such as cancer of the ovary, uterus, and cervix. The group's main objective is to provide an appropriate instrument to test new ideas from prevention of female pelvic malignancies and management of patients with such malignancies.
|
